Independent review discusses evidence supporting the use of betahistine to alleviate residual dizziness following physical repositioning procedures in benign paroxysmal positional vertigo (BPPV) ...

HAMILTON, BERMUDA / ACCESSWIRE / June 15, 2023 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet ...

Dose dependent improvement in balance tests over placebo in Part A of TRAVERS trial Improvement 1.9 to 2.4 times greater with highest dose than with placebo Trial to proceed with Part B to test AM-125 ...

Hamilton, Bermuda, October 13, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology ...

Altamira Therapeutics (NASDAQ:CYTO) stock soared ~62% on Wednesday after the company said detailed results from a phase 2 trial of AM-125 (intranasal betahistine) in surgery-induced acute vestibular ...

* AURIS MEDICAL - EXPECT TO RECEIVE TOP-LINE DATA FROM COMPLETED AM-201 TRIAL IN EARLY MAY AND INTERIM DATA FROM AM-125 TRIAL IN Q3 Source text for Eikon: Further company coverage: ...

The vertigo treatment pipeline is steadily advancing, with numerous companies exploring novel therapies targeting its complex causes. Common in older adults, vertigo is often managed with vestibular ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. BETAHISTINE VIATRIS contains the active ingredient betahistine ...